Mirion Technologies, Inc. (“Mirion”), a global provider of
detection, measurement, analysis and monitoring solutions to the
medical, nuclear, defense, and research end markets, today
announced the acquisition of the Dosimetry Badge brand—a small,
US-based distributor of personal dosimeter badges.
Headquartered in Melbourne, FL, Dosimetry Badge started as a
radiation consulting company and evolved into distributing
cost-effective dosimetry services to veterinary centers,
chiropractic clinics, hospitals, radiology centers, nuclear
medicine departments, and other industries that require regular
radiation monitoring of employees. The company recorded nearly
$500,000 in revenue for the 2020 calendar year, with over 2,000
customers relying on Dosimetry Badge solutions for accurate dose
reporting.
“Adding the distribution channels and user-base of Dosimetry
Badge to our organization will increase the stateside footprint of
our dosimetry product offering, contributing to the continued
growth of our industry-leading dosimetry operations,” says Lou
Biacchi, President of Mirion Dosimetry Services. “We look forward
to serving existing Dosimetry Badge customers while providing them
with the opportunity to explore the robust dosimetry options
available at Mirion.”
Mirion provides personal radiation monitoring services and
dosimetry solutions for a wide range of applications. Personal
dosimeters are typically worn by individuals (clipped to their
collar, torso, waist, wrist or worn as a ring on their finger) who
work with or around sources of ionizing radiation and are used to
measure, record, and track the radiation dose they are exposed to
while performing their job.
Mirion’s flagship innovation, the Instadose®* dosimetry
monitoring platform, is a SMARTER personal dosimeter technology
that eliminates the need to collect and return badges every wear
period. Providing on-demand and automatic dose reads and insights,
Instadose dosimeters enable instant access to current and
historical exposure data and cumulative dose insights, along with
the ability to make account, location, device, and wearer changes
online within minutes.
With the acquisition of the Dosimetry Badge brand and its
distribution contacts, Mirion will strengthen its position in the
US dosimetry market.
Mirion expects to complete its business combination with GS
Acquisition Holdings Corp II (NYSE: GSAH) and become a publicly
listed company in the second half of 2021, subject to satisfaction
of closing conditions, including certain regulatory approvals.
*Instadose® dosimeters may not be accredited in all countries.
Please call 800-251-3331 for more information about international
availability.
Resources
- For more information on ionizing radiation, visit:
https://www.mirion.com/learning-center/radiation-safety-basics/types-of-ionizing-radiation
- The International Atomic Energy Agency (IAEA) Safety Standards,
Occupational Radiation Protection, General Safety Guide (GSG-7) can
be viewed here:
https://www-pub.iaea.org/MTCD/Publications/PDF/PUB1785_web.pdf
- To learn more about how Instadose wireless dosimetry is
revolutionizing personal radiation monitoring, view this video:
https://www.youtube.com/watch?v=Mqyku6oFh3k
About Mirion
Mirion Technologies is a leading provider of detection,
measurement, analysis and monitoring solutions to the nuclear,
defense, medical and research end markets. The organization aims to
harness its unrivaled knowledge of ionizing radiation for the
greater good of humanity. Many of the company's end markets are
characterized by the need to meet rigorous regulatory standards,
design qualifications and operating requirements. Headquartered in
Atlanta (GA – USA), Mirion employs around 2,500 people and operates
in 13 countries. For more information, and for the latest news and
content from Mirion, visit Mirion.com. Mirion is currently a
portfolio company of Charterhouse Capital Partners, LLP.
About Dosimetry Badge
Dosimetry Badge is a proud distributor of high-quality personal
radiation badges. Originally founded in 1971 as a radiation
consulting company, Dosimetry Badge has continued to evolve and
expand its offerings over the years. With a strong emphasis on
quality, accuracy, and reliability, Dosimetry Badge serves over
2,000 users spanning a variety of industries. For more information,
visit www.dosimetrybadge.com.
About GSAH
GS Acquisition Holdings Corp II (NYSE: GSAH) is a special
purpose acquisition company formed for the purpose of effecting
merger, stock purchase or similar business combination with one or
more businesses. The company is sponsored by an affiliate of The
Goldman Sachs Group, Inc. In June 2020, GSAH completed its initial
public offering, raising $750 million from investors.
Forward-Looking Statements
This press release contains “forward-looking statements” within
the meaning of The Private Securities Litigation Reform Act of
1995. Forward-looking statements include, without limitation,
statements regarding the estimated future financial performance,
financial position and financial impacts of the potential
transaction, the satisfaction of closing conditions to the
potential transaction and the private placement, the level of
redemptions by GSAH’s public stockholders and purchase price
adjustments in connection with the potential transaction, the
timing of the completion of the potential transaction, the
anticipated pro forma enterprise value and Adjusted EBITDA of the
combined company following the potential transaction, anticipated
ownership percentages of the combined company’s stockholders
following the potential transaction, and the business strategy,
plans and objectives of management for future operations, including
as they relate to the potential transaction. Such statements can be
identified by the fact that they do not relate strictly to
historical or current facts. When used in this press release, words
such as “pro forma,” “anticipate,” “believe,” “continue,” “could,”
“estimate,” “expect,” “intend,” “may,” “might,” “plan,” “possible,”
“potential,” “predict,” “project,” “should,” “strive,” “would” and
similar expressions may identify forward-looking statements, but
the absence of these words does not mean that a statement is not
forward-looking. When GSAH or Mirion discusses its strategies or
plans, including as they relate to the potential transaction, it is
making projections, forecasts and forward-looking statements. Such
statements are based on the beliefs of, as well as assumptions made
by and information currently available to, GSAH’s or Mirion’s
management.
These forward-looking statements involve significant risk and
uncertainties that could cause the actual results to differ
materially from the expected results. Most of these factors are
outside GSAH’s and Mirion’s control and are difficult to predict.
Factors that may cause such differences include, but are not
limited to: (1) GSAH’s ability to complete the potential
transaction or, if GSAH does not complete the potential
transaction, any other initial business combination; (2)
satisfaction or waiver (if applicable) of the conditions to the
potential transaction, including with respect to the approval of
the stockholders of GSAH; (3) the ability to maintain the listing
of the combined company’s securities on the New York Stock
Exchange; (4) the inability to complete the private placement; (5)
the risk that the proposed transaction disrupts current plans and
operations of GSAH or Mirion as a result of the announcement and
consummation of the transaction described herein; (6) the ability
to recognize the anticipated benefits of the proposed transaction,
which may be affected by, among other things, competition, the
ability of the combined company to grow and manage growth
profitably, maintain relationships with customers and suppliers and
retain its management and key employees; (7) costs related to the
proposed transaction; (8) changes in applicable laws or regulations
and delays in obtaining, adverse conditions contained in, or the
inability to obtain necessary regulatory approvals required to
complete the potential transaction; (9) the possibility that GSAH
and Mirion may be adversely affected by other economic, business,
and/or competitive factors; (10) the outcome of any legal
proceedings that may be instituted against GSAH, Mirion or any of
their respective directors or officers, following the announcement
of the potential transaction; (11) the failure to realize
anticipated pro forma results or projections and underlying
assumptions, including with respect to estimated stockholder
redemptions, purchase price and other adjustments; (12) future
global, regional or local political, market and social conditions,
including due to the COVID-19 pandemic; and (13) other risks and
uncertainties indicated from time to time in the definitive proxy
statement of GSAH, including those under “Risk Factors” therein,
and other documents filed or to be filed with the Securities and
Exchange Commission (“SEC”) by GSAH.
Forward-looking statements included in this release speak only
as of the date of this release. Neither GSAH nor Mirion undertakes
any obligation to update its forward-looking statements to reflect
events or circumstances after the date of this release. Additional
risks and uncertainties are identified and discussed in GSAH’s
reports filed with the SEC and available at the SEC’s website at
http://www.sec.gov.
Additional Information about the Transaction and Where to
Find It
In connection with the proposed business combination, a
registration statement on Form S-4 was filed by GSAH with the SEC
and has been declared effective. The Form S-4 includes a proxy
statement in connection with the solicitation of proxies for the
vote by GSAH’s stockholders in connection with the proposed
business combination and other matters as described in the Form
S-4, as well as a prospectus relating to the offer of the
securities to be issued in connection with the completion of the
proposed business combination. GSAH and Mirion urge investors,
stockholders and other interested persons to read the Form S-4,
including the proxy statement/prospectus, as well as other
documents filed with the SEC in connection with the proposed
business combination, as these materials contain important
information about GSAH, Mirion and the proposed business
combination. GSAH’s stockholders are also be able to obtain copies
of such documents, without charge at the SEC’s website at
http://www.sec.gov, or by directing a request to:
IR-GSPCS@gs.com
Participants in the Solicitation
GSAH and Mirion, and their respective directors and officers,
may be deemed participants in the solicitation of proxies of GSAH
stockholders in connection with the proposed business combination.
GSAH’s stockholders and other interested persons may obtain,
without charge, more detailed information regarding the directors
and officers of GSAH in GSAH’s Annual Report on Form 10-K/A for the
fiscal year ended December 31, 2020, which was filed with the SEC
on May 17, 2021.
Information regarding the persons who may, under SEC rules, be
deemed participants in the solicitation of proxies to GSAH’s
stockholders in connection with the proposed business combination
and other matters to be voted upon at the special meeting is set
forth in the proxy statement/prospectus for the proposed business
combination. Additional information regarding the interests of
participants in the solicitation of proxies in connection with the
proposed business combination is included in the proxy
statement/prospectus that GSAH has filed with the SEC.
Contacts
View source
version on businesswire.com: https://www.businesswire.com/news/home/20211004005047/en/
For investor inquiries: GS Acquisition Holdings Corp II
Please email: IR-GSPCS@gs.com
For media inquiries: Phil Denning / Nora Flaherty E
MirionPR@icrinc.com
Leslie Shribman Goldman Sachs & Co. LLC T +1
212-902-5400
GS Acquisition Holdings ... (NYSE:GSAH)
Historical Stock Chart
From Aug 2024 to Sep 2024
GS Acquisition Holdings ... (NYSE:GSAH)
Historical Stock Chart
From Sep 2023 to Sep 2024